Clinical Trial Update: Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021) [Phase 2]

View source ↗

Summary

This phase 2 trial evaluated a fixed-dose combination of grazoprevir, uprifosbuvir, and ruzasvir in chronic hepatitis C patients who failed prior antiviral ther…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Grazoprevir (grazoprevir)
• Ruzasvir (ruzasvir)
• Uprifosbuvir (uprifosbuvir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis, Hepatitis C | Phase 2 | Status: TERMINATED | Results posted: 2018-03-20